Clinical Trial Update: Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial examining PSMA- or FACBC PET/CT–guided site-directed therapy for prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• FACBC (fluciclovine F-18) (fluciclovine F-18)
• PSMA PET tracer

Snippet

Sponsor: University of Washington | Conditions: Prostate Adenocarcinoma | Phase 2 | Status: RECRUITING